← FDA DRUG APPROVALS

FDA ANDA · ANDA207820

LEVALBUTEROL INHALATION SOLUTION

Sponsor: SUN PHARM

APPLICATION
ANDA207820
TYPE
ANDA
ORIGINAL APPROVAL
2018-11-05
LATEST ACTION
2019-12-20
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

LEVALBUTEROL HYDROCHLORIDEDiscontinued
LEVALBUTEROL HYDROCHLORIDE EQ 0.021% BASE · SOLUTION · INHALATION
LEVALBUTEROL HYDROCHLORIDEDiscontinued
LEVALBUTEROL HYDROCHLORIDE EQ 0.042% BASE · SOLUTION · INHALATION
LEVALBUTEROL HYDROCHLORIDEDiscontinued
LEVALBUTEROL HYDROCHLORIDE EQ 0.0103% BASE · SOLUTION · INHALATION

Approval history

2019-12-20Labeling · Supplement 2 · standardAP
2018-11-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →